Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

Clinical Pharmacology and Therapeutics
H TakahashiHirotoshi Echizen

Abstract

To determine whether genetic polymorphism of cytochrome P450 (CYP) 2C9 affects the in vivo metabolism of warfarin enantiomers. Eighty-six Japanese patients heart disease who were given warfarin participated in the study. Plasma unbound concentrations of warfarin enantiomers and urinary (S)-7-hydroxywarfarin concentrations were measured by means of a chiral HPLC and ultrafiltration technique to calculate the unbound oral clearance (CLpo,u) for the enantiomers and the formation clearance (CLm) for (S)-warfarin 7-hydroxylation. Genotyping for CYP2C9 (the wild type [wt], Arg144/Cys, and I1e359/Leu) and for CYP2C19 (wt, ml, and m2) was performed with a polymerase chain reaction method. Three patients were heterozygous for the CYP2C9 Leu359 mutation but none were homozygous for the mutation (the allele frequency of 0.017). None had a CYP2C9 Cys144 allele. The medians for (S)-warfarin CLpo,u and its 7-hydroxylation CLm obtained from heterozygotes of CYP2C9 Leu359 were significantly less than those obtained from homozygotes of the wt allele, as follows: 234 ml/min (range, 156 to 269 ml/min) versus 632 ml/min (range, 180 to 2070 ml/min) (p < 0.001) and 0.20 ml/min (range, 0.05 to 0.77 ml/min) versus 0.80 ml/min (range, 0.05 to 14.9 ml/m...Continue Reading

References

Oct 1, 1975·Clinical Pharmacology and Therapeutics·G R Wilkinson, D G Shand
Jun 27, 1991·The New England Journal of Medicine·J Hirsh
Jan 1, 1989·Pharmacology & Therapeutics·G R WilkinsonR A Branch
Aug 1, 1974·Clinical Pharmacology and Therapeutics·R A O'Reilly
Apr 1, 1974·Clinical Pharmacology and Therapeutics·A BreckenridgeR Gibbons
Jun 1, 1994·British Journal of Clinical Pharmacology·E ChanM Rowland
Feb 1, 1996·QJM : Monthly Journal of the Association of Physicians·H C YuK S Woo
Jun 1, 1996·Clinical Pharmacokinetics·S Harder, P Thürmann
Aug 1, 1996·Pharmacogenetics·T H Sullivan-KloseJ A Goldstein
Oct 1, 1996·Pharmacogenetics·M J StubbinsC R Wolf
Dec 1, 1996·Clinical Pharmacology and Therapeutics·T KubotaT Ishizaki
Jan 1, 1997·Pharmacology & Therapeutics·L S Kaminsky, Z Y Zhang
Nov 14, 1997·Pharmacogenetics·K NasuT Ishizaki

❮ Previous
Next ❯

Citations

Oct 19, 2006·Human Genetics·Mia WadeliusPanos Deloukas
May 5, 2001·The New England Journal of Medicine·A J Wood
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·J H Lin, A Y Lu
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·H G XieC M Stein
Nov 20, 2002·Pharmacogenomics·Omer Iqbal
Feb 16, 2011·International Heart Journal·You MiyagataYoshiki Sugiyama
Oct 8, 1999·Pharmacotherapy·K L ShekE Nutescu
Jan 17, 2002·Pharmacotherapy·Aharon BlochYoseph Caraco
Oct 22, 2010·Drug Metabolism and Pharmacokinetics·Shinya UchidaHiroshi Watanabe
Nov 19, 2010·Drug Metabolism and Pharmacokinetics·Onkar SinghBalram Chowbay
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Larisa H CavallariAdam Bress
Jul 15, 2005·Pharmacogenomics·Deepak VooraBrian F Gage
Aug 9, 2012·Future Cardiology·Larisa H Cavallari, Minoli A Perera
Apr 13, 2011·Expert Opinion on Drug Metabolism & Toxicology·Drew R Jones, Grover P Miller
Dec 17, 2015·Pharmacogenomics·Addepalli PavaniVijay Kumar Kutala
May 26, 2006·British Journal of Clinical Pharmacology·Farhad Kamali, Munir Pirmohamed
Nov 30, 2011·Pharmacotherapy·Larisa H CavallariMinoli A Perera
Oct 24, 2006·British Journal of Clinical Pharmacology·N K ZgheibR A Branch
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Nov 28, 2013·Expert Opinion on Drug Metabolism & Toxicology·Andrew Rowland, Arduino A Mangoni
Jul 25, 2006·Expert Opinion on Pharmacotherapy·Issam Zineh, Julie A Johnson
Sep 29, 2012·The EPMA Journal·Liliya Alexandrovna BelozercevaValentin Viktorovich Vlasov
Dec 21, 2016·Pharmacogenomics·Harumi TakahashiHirotoshi Echizen
May 30, 2003·The Annals of Pharmacotherapy·William E Dager
May 19, 2009·Journal of Gastroenterology·Akiko ShiotaniKen Haruma
Mar 7, 2017·International Journal of Cardiology·Kyung Eun LeeHye Sun Gwak
Sep 27, 2007·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Andrea R RedmanYuen Yi Hon
Apr 20, 2004·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Andrea R RedmanYuen Yi Hon
Nov 18, 2003·British Journal of Clinical Pharmacology·Lynn PurkinsDon Nichols
Dec 26, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Takashi NozawaKatsusuke Yano
Sep 20, 2006·The Pharmacogenomics Journal·M Wadelius, M Pirmohamed
Sep 3, 2004·Journal of Clinical Pharmacology·Kiman KimHartmut Derendorf
Aug 3, 2004·Journal of Clinical Pharmacology·Rubén Burgos-VargasDietrich Tuerck
Feb 8, 2002·Journal of Clinical Pharmacology·Paul R Casner, Eduardo Sandoval
Mar 19, 2005·European Journal of Clinical Pharmacology·Heydy V Bravo-VillaltaRyuya Horiuchi
Apr 28, 2005·The Annals of Pharmacotherapy·Mai-Trang N DangSteven R Kayser

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.